Director Richard J. Daly filed a Form 4 with the SEC on November 12, 2026, reporting two open market purchases of Aquestive Therapeutics, Inc. common stock on November 10, 2026.

Key Highlights

  • First purchase: Richard J. Daly acquired 1,200 shares of common stock at $3.53 per share on November 10, 2026.
  • Second purchase: Daly acquired an additional 26,825 shares at $3.545 per share on the same date.
  • Total beneficial ownership: Following both transactions, Daly directly holds 28,025 shares of common stock.
  • Transaction type: Both purchases were open market transactions, as noted in the filing's explanation of responses.
  • Issuer: Aquestive Therapeutics, Inc., listed as NASDAQ:AQST.

Richard J. Daly's Open Market Purchases of Aquestive Therapeutics Common Stock

According to the Form 4 filed on November 12, 2026, Richard J. Daly, identified as a director of Aquestive Therapeutics, Inc. (NASDAQ:AQST), reported two purchases of the company's common stock executed on November 10, 2026. The filing states that both transactions were made in open market purchases. The form was signed by Thomas Zalewski as Attorney-In-Fact on behalf of the reporting person.

In the first transaction, the filing reports that Daly acquired 1,200 shares at a price of $3.53 per share, bringing his directly held beneficial ownership to 1,200 shares. In the second transaction, he acquired 26,825 shares at $3.545 per share. Following both reported transactions, the filing states his total direct beneficial ownership stands at 28,025 shares of common stock. No derivative securities transactions were reported in Table II of the filing.

The filing was submitted pursuant to Section 16(a) of the Securities Exchange Act of 1934. No amendment to a prior filing was indicated, and the form was filed by one reporting person. The reporting person's address is listed as c/o Aquestive Therapeutics, Inc., 184 Liberty Corner Drive, Suite 305, Warren, New Jersey 07059.

What Was Disclosed

Director Richard J. Daly disclosed two open market purchases of Aquestive Therapeutics common stock on November 10, 2026, totaling 28,025 shares acquired at prices of $3.53 and $3.545 per share, resulting in direct beneficial ownership of 28,025 shares.